Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

March 8, 2023

Study Completion Date

March 8, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

Enasidenib

100 mg enasidenib (CC-90007)

Trial Locations (3)

Local Institution - 003, Orlando

Local Institution - 002, Miami

Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville